Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the pharmacokinetics of R/S Methadone.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Methadone

Criteria

Inclusion Criteria:

• Males or females, without evidence of infection with HIV,HBV or HCV, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start.

Exclusion Criteria:

• Evidence of chronic diseases including HIV, HBV or HCV.

• Evidence of acute or chronic liver disease.

• Treatment with prescription or nonprescription drugs other than methadone within 7 days.